Company: IXHL
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001213900-25-036057
Chunk: 17

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 17
---
 reduce the number of shares issuable upon exercise of the Series A Warrant by a number of shares having an aggregate value equal to the exercise price. The number of shares issuable upon exercise of the Series A Warrants is subject to adjustment in connection with the adjustment of the exercise price of the Series A Warrants, as described below, to a number of shares that is up to 10 times the number of shares underlying the Series A Warrant at issuance. The number of shares issuable pursuant to the Series A Warrants, including by way of its zero exercise price provisions, is also subject to proportional adjustments for stock splits, dividends, reclassifications and similar adjustments. The Pre -FundedWarrants and Series A Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation (4.99% or 9.99%); provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving 61 days’ notice to the Company, but not to any percentage in excess of 9.99%. On March 10, 2025 and in connection with the Private Placement, we entered into a registration rights agreement with the investors pursuant to which we agreed to register for resale the shares of common stock issued and Warrants Shares issuable in connection with the Private Placement. We have filed a resale registration statement and intend to file an additional resale registration statements following receipt of the Warrant Stockholder Approval to fulfill these obligations. 10 On March 7, 2025, we also entered into a placement agency agreement (the “Placement Agreement”) with R.F. Lafferty & Co., Inc. (“R.F. Lafferty”), pursuant to which we engaged R.F. Lafferty to act as sole placement agent in connection with the Private Placement. As compensation to the placement agent, we paid R.F. Lafferty commission equal to 7.0% of the aggregate gross proceeds from the Private Placement. In addition, we agreed to reimburse R.F. Lafferty for certain of out -of -pocketexpenses, including for reasonable legal fees and disbursements for its counsel. The Private Placement closed on March 10, 2025. The net proceeds to us from the Private Placement were approximately $11.3 million, after deducting placement agent fees and other expenses associated with the Private Placement and payable by us and prior to the repayment of $3.9 million